Page 54 - Lipids News Today

The small interfering RNA product showed reductions of more than 95% in levels of Lp(a) at doses of 75 mg or more when given every 12 weeks in a new phase 2 study.

In the phase 3 PROMINENT trial, pemafibrate improved multiple lipid fractions in patients with type 2 diabetes, without any impact on cardiovascular events.

Although the open-label trial has many limitations, it could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose eicosapentaenoic acid.

A new study published in the journal Science Advances sheds light on how Gram-negative bacteria like E. coli construct their outer membrane to resemble body armor, which has far-reaching implications for the development of antibiotics.

Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer. However, immune checkpoint inhibition therapy is only effective in 20%–30% of cancer patients, so developing better drug delivery systems to induce anticancer cellular immunity is necessary.

Aging involves complicated plot twists and a large cast of characters: inflammation, stress, metabolism changes, and many others. Now, a team of Salk Institute and UC San Diego scientists reveal another factor implicated in the aging process-;a class of lipids called SGDGs (3-sulfogalactosyl diacylglycerols) that decline in the brain with age and may have anti-inflammatory effects.

Dementia encompasses a range of neurodegenerative conditions that lead to memory loss and cognitive deficiencies and affect some 55 million people worldwide.

The 10th annual Appel Alzheimer's Disease Research Institute Symposium brought fascinating reports of progress in understanding Alzheimer's and related neurodegenerative diseases.

Researchers at Oregon State University and Oregon Health & Science University have taken a key step toward improving and lengthening the lives of cystic fibrosis patients, who experience chronically clogged airways and a dramatically shortened life expectancy.

A study tested the hypothesis that the ACE-2 receptor of SARS-CoV-2 is not only an attachment factor in viral infection but also plays a role in activating the viral spike protein to facilitate membrane fusion.